Krishnan A, Walsh D. Improving predictive accuracy of early recurrence in pancreatic ductal adenocarcinoma: Role of postoperative serum tumor markers. World J Gastrointest Surg 2025; 17(1): 101549 [DOI: 10.4240/wjgs.v17.i1.101549]
Corresponding Author of This Article
Arunkumar Krishnan, Assistant Professor, MD, Department of Supportive Oncology, Atrium Health Levine Cancer, 1021 Morehead Medical Drive, Suite 70100, Charlotte, NC 28204, United States. dr.arunkumar.krishnan@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Jan 27, 2025; 17(1): 101549 Published online Jan 27, 2025. doi: 10.4240/wjgs.v17.i1.101549
Improving predictive accuracy of early recurrence in pancreatic ductal adenocarcinoma: Role of postoperative serum tumor markers
Arunkumar Krishnan, Declan Walsh
Arunkumar Krishnan, Declan Walsh, Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC 28204, United States
Arunkumar Krishnan, Department of Medicine, Section of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27103, United States
Author contributions: Krishnan A contributed to the concept of the study and drafted the manuscript; Krishnan A and Walsh D revised the manuscript, and reviewed and approved the final version.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Arunkumar Krishnan, Assistant Professor, MD, Department of Supportive Oncology, Atrium Health Levine Cancer, 1021 Morehead Medical Drive, Suite 70100, Charlotte, NC 28204, United States. dr.arunkumar.krishnan@gmail.com
Received: September 18, 2024 Revised: October 17, 2024 Accepted: November 14, 2024 Published online: January 27, 2025 Processing time: 99 Days and 23.3 Hours
Core Tip
Core Tip: A study by He et al published a serum tumor markers-based nomogram to predict early recurrence in patients with pancreatic ductal adenocarcinoma following radical surgery. This model incorporates markers such as carbohydrate antigen 19-9 and carcinoembryonic antigen, which could significantly improve the accuracy of recurrence prediction compared to using only preoperative markers. The nomogram provides a valuable tool for categorizing patients and guiding the use of adjuvant therapy, addressing an important need in the management of this aggressive form of cancer. While the findings are promising, validating the model further using diverse and larger patient cohorts and considering including additional factors to maximize its clinical relevance and applicability is recommended.
